Mitsubishi Electric has agreed to acquire the remaining shares of Polish rail-equipment manufacturer MEDCOM through wholly owned Mitsubishi Electric Europe B.V., a transaction that would give the Japanese group 100% ownership. Completion is targeted for the first half of the fiscal year ending March 2027 and remains subject to the required regulatory approvals. The announcement is therefore a signed expansion of control, not a completed transfer.
MEDCOM designs, manufactures, sells and maintains auxiliary power supply systems, propulsion control systems and other power-electronics equipment for railcars and electric urban transport. Established in 1988 and based in Warsaw, the company employed about 450 people as of June 2026. Its manufacturing and service capabilities give Mitsubishi a European operating platform rather than only a distribution channel.
The companies have worked together since Mitsubishi Electric’s initial investment in MEDCOM in 2016. MEDCOM has incorporated Mitsubishi silicon-carbide power devices into rail products that deliver higher output while reducing size and weight. Full ownership would bring the semiconductor component, system engineering, production and maintenance relationship inside a single corporate perimeter.
Mitsubishi says the change should speed decisions, improve operating efficiency and strengthen competitiveness. That objective is particularly relevant in rail procurement, where equipment must be adapted to rolling-stock platforms, certified for local requirements and supported over long service lives. A wholly owned MEDCOM can give the group a closer link between European customer specifications and Mitsubishi’s wider technology portfolio.
The industrial logic rests on European rail investment. The company identifies Europe as the world’s largest rail market, while high-speed corridors, Polish network expansion and the replacement of aging vehicles and electrical systems are sustaining demand. Rail and electric urban transport also benefit from public policies that favor lower-emission passenger and freight mobility.
Mitsubishi intends to make MEDCOM’s high-performance power electronics a core technology and use the Polish business to develop and manufacture components and solutions. The ambition extends beyond rolling stock into other infrastructure applications, meaning the acquisition is also a platform decision: it places engineering capacity close to European projects where power conversion and compact electrical systems are increasingly important.
Important transaction economics remain undisclosed. Mitsubishi did not state the price, the size of the stake it already owns, MEDCOM’s revenue or the financing method, so investors cannot calculate an acquisition multiple, control premium or immediate earnings contribution. Integration must also preserve MEDCOM’s customer relationships and specialist workforce while aligning product development and capital allocation with the larger group.
The next binding steps are regulatory clearance and transfer of the remaining shares before the expected closing window. After completion, the measurable tests will be the allocation of production and research work, the treatment of MEDCOM’s brand and management, new rail contracts and any expansion into adjacent infrastructure. Until approvals are secured, Mitsubishi has an agreement to reach full ownership, not yet the completed consolidation it is seeking.
